RXRX Recursion Pharmaceuticals
- 6.870
- +0.050+0.73%
Recursion Pharmaceuticals News
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $10
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $11
A Quick Look at Today's Ratings for Recursion Pharmaceuticals(RXRX.US), With a Forecast Between $8 to $14
Recursion Pharmaceuticals Maintains Buy Rating Amidst Modest Study Results and Strong Financial Position
Hold Rating on Recursion Pharmaceuticals Amidst Lukewarm Phase 2 Results and AI Platform Validation Concerns
Recursion Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10
Recursion Pharmaceuticals (RXRX) Gets a Hold From Morgan Stanley
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Strategic Merger and Financial Prospects Affirm Buy Rating for Recursion Pharmaceuticals
Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16
Recursion Pharmaceuticals Analyst Ratings
Recursion Pharmaceuticals (RXRX) Receives a Hold From TD Cowen
Recursion Pharmaceuticals Analyst Ratings
Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target
Recursion Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals: A Buy Rating With Growth and Innovation on the Horizon
Recursion Pharmaceuticals Analyst Ratings
Analysis
Price Target
No Data
No Data
